Remove stat-plus
article thumbnail

STAT+: White House to hold a listening session on reforming pharmacy benefit managers

STAT

Among those invited is Mark Cuban, whose Cost Plus Drug Company is trying to transform the marketplace by avoiding the largest middlemen when reaching benefits agreements with employers. Continue to STAT+ to read the full story…

Insurance 145
article thumbnail

STAT+: Profiting from ‘legal’ insider trading isn’t always easy

STAT

STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. Plus, biotech watercooler updates on Vera Therapeutics and Biohaven Pharma. As always, send feedback and questions to  BiotechScorecard@statnews.com Continue to STAT+ to read the full story…

93
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: AstraZeneca picks up rare-disease focused Amolyt Pharma in $1 billion deal

STAT

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.     Continue to STAT+ to read the full story…

123
123
article thumbnail

STAT+: Argenx readies another blockbuster opportunity with its antibody drug

STAT

It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. Plus, a few dashes of fun. Continue to STAT+ to read the full story… One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week?

127
127
article thumbnail

STAT+: A preview of Intra-Cellular Therapies’ depression drug, and sizing up the MASH opportunity

STAT

It’s called Adam’s Biotech Scorecard, and it’s exclusively for STAT subscribers. Plus, a few dashes of fun. Continue to STAT+ to read the full story… One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week?

106
106
article thumbnail

STAT+: A deep dive into Applied Therapeutics’ data, and questions on Cassava’s erased data

STAT

It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. Plus, a few dashes of fun. Continue to STAT+ to read the full story… One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week?

120
120
article thumbnail

STAT+: Many costly generic drugs are unavailable at Amazon, Cuban, and other alternative pharmacies

STAT

A growing number of alternative pharmacies — such as those run by Costco, Amazon, and Mark Cuban Cost Plus Drugs — may be increasingly popular with American consumers, but a new analysis finds many of the most expensive generic medicines are unavailable, prices vary widely, and savings can be modest.